N4 Pharma greatly encouraged by the oral delivery of Nuvec results

N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided an update on its ongoing Australian Research Council grant work with the University of Queensland, investigating the oral delivery of Nuvec® loaded with DNA.

The Company has now completed two in vivo studies demonstrating that Nuvec loaded with OVA m-cherry DNA and encapsulated within an acid protective polymer can be dosed orally, penetrate the mucus layer and successfully express the OVA m-cherry locally in the intestine epithelial cells.

In the first study Nuvec® was formulated together with the OVA and the whole formulation was coated with the polymer as a capsule. In the second study the nanoparticles, once loaded with OVA, were individually encapsulated with the polymer and administered via an oral gavage.

Nigel Theobald, Chief Executive Officer of N4 Pharma, commented:

“These studies are at an early stage in the development of an oral application, but show the versatility of Nuvec both in terms of its ease of formulation and application in a wide number of areas. Having successfully demonstrated Nuvec can be administered orally and locally transfect cells in the intestine, the next step is to investigate what the most suitable medical application might be for this delivery method.

We are greatly encouraged by these early results and look forward to continuing the work in this area, whilst continuing with our ongoing siRNA work.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Share on facebook
    Facebook
    Share on twitter
    Twitter
    Share on linkedin
    LinkedIn
    N4 Pharma

    More articles like this

    N4 Pharma

    N4 Pharma plc Nuvec® R&D and Strategy Update

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided an encouraging update on its ongoing in vitro siRNA research work. The Company’s double loaded siRNA work is ongoing and

    N4 Pharma

    N4 Pharma launch Interactive Investor Hub

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced the launch of the N4 Pharma Interactive Investor Hub. For both existing and prospective shareholders, the new

    N4 Pharma

    N4 Pharma updated investor presentation

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced that an updated investor presentation incorporating the Company’s acquisition of a 71% interest in Nanogencis Limited is

    N4 Pharma

    N4 Pharma acquires of a controlling interest in Nanogenics

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for oncology, gene therapy and vaccines, has announced the acquisition of a controlling interest, through a subscription for new ordinary shares, in Nanogenics Limited, a company

    N4 Pharma

    N4 Pharma granting of patent application in the United States

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced two operational updates. Granting of further US patent The University of Queensland has informed the Company that it has

    N4 Pharma

    N4 Pharma updates on in vitro results for Nuvec®

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided a further update on its ongoing in vitro siRNA research work. BCL-2 assay has been established Further to the

    N4 Pharma

    N4 Pharma Nuvec well suited for working with siRNA

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided an update on its ongoing siRNA research work. The Company has completed the single loading of both

    N4 Pharma

    N4 Pharma well funded to deliver its siRNA programme

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced its audited results for the year ended 31 December 2022. Highlights: • Nuvec® as a delivery system

    N4 Pharma

    N4 Pharma AGM to be held on 3 April 2023

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced that its Annual Report and Accounts for the year ended 31 December 2022 and Notice of its

    N4 Pharma

    N4 Pharma Broker Offer to raise a maximum of £1 million

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided an opportunity for shareholders and other investors who did not participate in the fundraising announced today to

    N4 Pharma

    N4 Pharma raises £1million through a placing

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced that it has raised £1 million (before expenses) through a placing of 50,000,000 new ordinary shares of

    N4 Pharma

    N4 Pharma updates on patent filing

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided an update on its patent application for Nuvec®, filed in March 2020 (no. PCT/GB2021/050960 Gene Therapy Vectors).

    N4 Pharma

    N4 Pharma successful Nuvec double siRNA testing

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced successful in vitro testing of Nuvec® loaded with two small interfering RNA (siRNA) probes. On 14 September 2022, the Company

    N4 Pharma

    N4 Pharma continue to make excellent progress

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for vaccines and cancer treatments, has announced its unaudited interim results for the six months ended 30 June 2022. Highlights: ·      Exciting opportunities identified for

    N4 Pharma

    N4 Pharma plans for commercialising Nuvec (VIDEO)

    N4 Pharma plc (LON:N4P) CEO Nigel Theobald chats to DirectorsTalk Interviews about its development plans for commercialising Nuvec. Nigel talks us through the update highlights, explains why companies working with siRNA are much more open to using novel delivery

    No more posts to show